Maysa Mahmoud Abu-Khalaf, MBBS

Associate Professor of Medicine (Medical Oncology) and of Obstetrics, Gynecology, and Reproductive Sciences

Clinical Interests

  • Breast Neoplasms
  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult; Adolescent
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Breast Center at Smilow Cancer Hospital

Medical Oncology: Subset Medical Oncology Faculty

Yale Medical Group

Clinical Trials

Conditions Study Title
Breast - Female, Breast - Male Doxorubicin+Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in TNBC Patients
Breast - Female, Breast - Male Neoadjuvant MEDI4736 with nab-paclitaxel followed by ddAC for stage 1-3 TNBC
Breast - Female, Breast - Male Phase II trial of MK-3475 as Monotherapy for mTNBC
Breast - Female Randomized study comparing MPDL3280A with Nab-Paclitaxel compared to placebo with Nab-Paclitaxel
Breast - Female GDC0810 in Postmenopausal Women w/ Locally Advanced/Metastatic Estrogen Recep Positive breast cancer
Breast - Female, Breast - Male Olaparib as Adjuvant Treatment in Patients With BRCA Mutated High Risk HER2 Negative breast cancer
Breast - Female, Breast - Male MM-302 Plus Trastuzumab vs. Chemotherapy Plus Trastuzumab in HER2-positive MBC
Breast - Female Neoadj ph 2 AI plus everolimus in postmenopausal women w/ ER pos/HER2 neg, low risk score
Breast - Female, Breast - Male Phase 2, open label study of Lucitanib in FGF abberrant metastatic breast cancer
Breast - Female, Breast - Male Phase II with Orteronel as Monotherapy for Metastatic Breast Cancer that expresses Androgen Receptor
Breast - Female Phase I Study of SGN-LIV1A via IV Infusion in Patients with LIV-1-positive Metastatic Breast Cancer
Breast - Female, Breast - Male S1207 Phase 3 Rand, Adj Endocrine Tx plus Everolimus in High risk ER/PR + HER2neg BC
Breast - Female, Breast - Male THE INFORM: BRCA1/2 STUDY: INVESTIGATION OF NEOADJUVANT CHEMOTHERAPY FOR MUTATION CARRIERS: BRCA1/2
Breast - Female, Breast - Male Phase I with GDC-0032 for Tx of Local Advanced or Metastatic Solid Tumors or HER2+ Breast Cancer
Breast - Female Neo-Adj, Phase 2, Pertuzumab and Trastuzumab with weekly Paclitaxel and FEC, HER2-pos Breast Cancer
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid PCD4989g: Phase I, Open-label MPDL3280A in solid tumors
Breast - Female, Breast - Male Breast Cancer Molecular Analysis Prior to Investigational Therapy (MAP-IT)

Edit this profile

Contact Info

Maysa Mahmoud Abu-Khalaf, MBBS
Patient Care Locations
Yale Medical OncologySmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 7th & 8th Floor

New Haven, CT 06511
View on map...
Yale Breast Cancer ProgramSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 4th Floor

New Haven, CT 06511
View on map...
Office Location
Fitkin Memorial Pavilion
789 Howard Avenue, Ste Suite 125

New Haven, CT 06519
View on map...
Mailing Address
Yale Cancer CenterPO Box 208028
333 Cedar Street

New Haven, CT 06520-8028